The closing price of Bluebird bio Inc (NASDAQ: BLUE) was $1.42 for the day, up 6.77% from the previous closing price of $1.33. On the day, 29242981 shares were traded.
Ratios:
Our analysis of BLUE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 1.55. In the meantime, Its Debt-to-Equity ratio is 1.36 whereas as Long-Term Debt/Eq ratio is at 1.04.
On December 08, 2023, Morgan Stanley Upgraded its rating to Equal-Weight which previously was Underweight and also upped its target price recommendation from $3 to $7.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 04 ’24 when Obenshain Andrew sold 6,095 shares for $1.53 per share. The transaction valued at 9,311 led to the insider holds 279,998 shares of the business.
Klima Thomas J sold 4,573 shares of BLUE for $6,986 on Mar 04 ’24. The insider now owns 124,840 shares after completing the transaction at $1.53 per share. On Mar 01 ’24, another insider, Colvin Richard A, who serves as the Chief Medical Officer of the company, sold 6,770 shares for $1.53 each. As a result, the insider received 10,342 and left with 118,368 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BLUE now has a Market Capitalization of 273.69M and an Enterprise Value of 403.11M. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.60 while its Price-to-Book (P/B) ratio in mrq is 0.68. Its current Enterprise Value per Revenue stands at 18.55 whereas that against EBITDA is -3.06.
Stock Price History:
Over the past 52 weeks, BLUE has reached a high of $5.53, while it has fallen to a 52-week low of $0.88. The 50-Day Moving Average of the stock is 1.2610, while the 200-Day Moving Average is calculated to be 2.7866.
Shares Statistics:
BLUE traded an average of 13.01M shares per day over the past three months and 10.69M shares per day over the past ten days. A total of 192.74M shares are outstanding, with a floating share count of 189.83M. Insiders hold about 1.51% of the company’s shares, while institutions hold 67.23% stake in the company. Shares short for BLUE as of Feb 29, 2024 were 34.13M with a Short Ratio of 2.62, compared to 27.5M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 17.71% and a Short% of Float of 18.91%.
Earnings Estimates
The firm’s stock currently is rated by 11 analysts. On average, analysts expect EPS of -$0.66 for the current quarter, with a high estimate of -$0.38 and a low estimate of -$0.98, while EPS last year was $0.38. The consensus estimate for the next quarter is -$0.5, with high estimates of -$0.24 and low estimates of -$0.85.
Analysts are recommending an EPS of between -$1 and -$2.26 for the fiscal current year, implying an average EPS of -$1.72. EPS for the following year is -$1.77, with 13 analysts recommending between -$0.95 and -$3.09.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 10 analysts. It ranges from a high estimate of $21.5M to a low estimate of $11.51M. As of the current estimate, Bluebird bio Inc’s year-ago sales were $62k, an estimated increase of 26,706.50% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $20.12M, an increase of 745.00% less than the figure of $26,706.50% in the same quarter last year. There is a high estimate of $29.2M for the next quarter, whereas the lowest estimate is $12.2M.
A total of 13 analysts have provided revenue estimates for BLUE’s current fiscal year. The highest revenue estimate was $49M, while the lowest revenue estimate was $33.18M, resulting in an average revenue estimate of $40.56M. In the same quarter a year ago, actual revenue was $3.6M, up 1,027.60% from the average estimate. Based on 14 analysts’ estimates, the company’s revenue will be $125.77M in the next fiscal year. The high estimate is $173M and the low estimate is $56.72M. The average revenue growth estimate for next year is up 210.10% from the average revenue estimate for this year.
